The estimated Net Worth of Bradley Albert Margus is at least $5.29 Million dollars as of 25 August 2021. Mr. Margus owns over 29,940 units of Arvinas Inc stock worth over $49,780 and over the last 6 years he sold ARVN stock worth over $5,018,444. In addition, he makes $225,236 as Independent Director at Arvinas Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Margus ARVN stock SEC Form 4 insiders trading
Bradley has made over 4 trades of the Arvinas Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 29,940 units of ARVN stock worth $2,545,199 on 25 August 2021.
The largest trade he's ever made was selling 40,000 units of Arvinas Inc stock on 18 March 2020 worth over $1,498,400. On average, Bradley trades about 13,419 units every 118 days since 2018. As of 25 August 2021 he still owns at least 2,000 units of Arvinas Inc stock.
You can see the complete history of Mr. Margus stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bradley Margus biography
Bradley Albert Margus is Independent Director of the company. Mr. Margus co-founded Cerevance, Inc., a drug discovery company, and has served as its Chief Executive Officer since October 2016. Mr. Margus also served as the Chief Executive Officer of Genome Bridge, a non-profit subsidiary of the Broad Institute of Massachusetts Institute of Technology and Harvard University, from January 2013 to June 2015 and as a co-founder and the Chief Executive Officer of Envoy Therapeutics from October 2009 to November 2012, when it was acquired by Takeda Pharmaceuticals. Mr. Margus holds an M.B.A. from Harvard University and a B.A. in government and business from George Washington University.
What is the salary of Bradley Margus?
As the Independent Director of Arvinas Inc, the total compensation of Bradley Margus at Arvinas Inc is $225,236. There are 11 executives at Arvinas Inc getting paid more, with John Houston having the highest compensation of $5,485,840.
How old is Bradley Margus?
Bradley Margus is 59, he's been the Independent Director of Arvinas Inc since 2013. There are 6 older and 12 younger executives at Arvinas Inc. The oldest executive at Arvinas Inc is Laurie Smaldone Alsup, 66, who is the Independent Director.
What's Bradley Margus's mailing address?
Bradley's mailing address filed with the SEC is C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN, CT, 06511.
Insiders trading at Arvinas Inc
Over the last 6 years, insiders at Arvinas Inc have traded over $123,187,141 worth of Arvinas Inc stock and bought 3,567,290 units worth $69,124,444 . The most active insiders traders include Capital Management, L.P.Ra ..., Liam Ratcliffe, and Kush Parmar. On average, Arvinas Inc executives and independent directors trade stock every 22 days with the average trade being worth of $1,884,820. The most recent stock trade was executed by John G Houston on 23 February 2024, trading 5,196 units of ARVN stock currently worth $244,472.
What does Arvinas Inc do?
arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.
What does Arvinas Inc's logo look like?
Complete history of Mr. Margus stock trades at Arvinas Inc
Arvinas Inc executives and stock owners
Arvinas Inc executives and other stock owners filed with the SEC include:
-
John Houston,
President, Chief Executive Officer, Director -
Sean Cassidy,
Chief Financial Officer -
Ian Taylor,
Chief Scientific Officer -
Ronald Peck,
Chief Medical Officer -
Dr. John G. Houston Ph.D.,
CEO, Pres & Director -
Dr. Ronald A. Peck,
Chief Medical Officer -
Dr. Ian Taylor Ph.D.,
Chief Scientific Officer -
Sean A. Cassidy CPA, M.B.A., CPA,
CFO & Treasurer -
Laurie Smaldone Alsup,
Independent Director -
Leslie Norwalk,
Independent Director -
Timothy Shannon,
Independent Chairman of the Board -
Bradley Margus,
Independent Director -
Briggs Morrison,
Independent Director -
Liam Ratcliffe,
Independent Director -
Edward Kennedy,
Independent Director -
Wendy Dixon,
Director -
Linda Bain,
Director -
Steve Weiss,
VP of HR -
Dr. Randy Teel Ph.D.,
Sr. VP of Corp. & Bus. Devel. -
Dr. Robert Kleinfield,
Chief Devel. Officer -
Matthew Batters J.D.,
Gen. Counsel -
Jeff Boyle,
VP of Investor Relations -
Dr. Craig M. Crews,
Founder, Chief Scientific Advisor & Member of Scientific Advisory Board -
Ventures Iii, L.P.5 Am Part...,
-
David K Loomis,
Chief Accounting Officer -
Sunil Agarwal,
Director -
Ix L.P.Canaan Partners Ix L...,
-
Capital Management, L.P.Ra ...,
-
Jakob Loven,
Director -
Andrew Crew,
See Remarks -
Ventures Iii, L.P.5 Am Co I...,
-
James E Deerfield Mgmt L.P....,
-
Craig Martin Crews,
10% owner -
Kush Parmar,
Director -
Angela M Cacace,
Chief Scientific Officer -
John D Young,
Director -
Everett Cunningham,
Director -
Noah Berkowitz,
Chief Medical Officer -
Randy Teel,
Int. Chief Financial Officer